期刊
NEURODEGENERATIVE DISEASE MANAGEMENT
卷 5, 期 1, 页码 27-35出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NMT.14.38
关键词
antiparkinsonian agents; dopamine agonists; genetic polymorphism; Parkinson's disease; personalized medicine; pharmacogenetics; pharmacogenomics
Recently, a lot of progress has been made in the identification of genetic biomarkers of drug response. Efforts to define the role of genetic polymorphisms in optimizing pharmacotherapy of Parkinson's disease were also undertaken. This report presents the current state of knowledge on pharmacogenetics of PD, including genes encoding enzymes involved in drug metabolism, drug transporters and direct targets of antiparkinsonian drugs. In most of cases, available data on pharmacogenetic factors that could turn out to be significant modifiers of therapy with anti-PD drugs is still very incomplete and makes it impossible to reach final conclusion about their usefulness in the clinic. More extensive studies, in more uniform, large patient groups, including genome-wide association studies, should be undertaken to finally confirm or deny the value of genetic tests in PD therapy individualization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据